Ednan K Bajwa1, Jessica A Volk, David C Christiani, R Scott Harris, Michael A Matthay, B Taylor Thompson, James L Januzzi. 1. 1Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA. 2Department of Medicine, Massachusetts General Hospital, Boston, MA. 3Department of Environmental Health, Harvard School of Public Health, Boston, MA. 4Department of Anesthesia, University of California San Francisco, San Francisco, CA. 5Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Abstract
OBJECTIVES: Soluble suppression of tumorigenicity-2 is a biomarker of myocardial strain and inflammation. The characteristics of acute respiratory distress syndrome include inflammation and cardiovascular dysfunction. We sought to determine whether plasma soluble suppression of tumorigenicity-2 concentration is associated with outcome and response to conservative fluid management and whether soluble suppression of tumorigenicity-2 concentration discriminates acute respiratory distress syndrome from decompensated heart failure. DESIGN: A retrospective analysis of the Fluid and Catheter Treatment Trial, a multi-center randomized controlled trial of conservative fluid management in the acute respiratory distress syndrome, as well as of a cohort of patients with decompensated heart failure. SETTING:Twenty acute care hospitals. PATIENTS: Eight hundred twenty-six patients with acute respiratory distress syndrome and 209 patients with acutely decompensated heart failure. MEASUREMENTS AND MAIN RESULTS: Nonsurvivors had higher day 0 (p < 0.0001) and day 3 (p < 0.0001) soluble suppression of tumorigenicity-2 concentrations. After adjustment for severity of illness, higher soluble suppression of tumorigenicity-2 concentration was associated with mortality, with odds ratioadj 1.47 (95% CI, 0.99-2.20; p = 0.06) at day 0, 2.94 (95% CI, 2.00-4.33; p < 0.0001) at day 3, and 3.63 (95% CI, 2.38-5.53; p < 0.0001) if soluble suppression of tumorigenicity-2 increased between days. Cumulative fluid balance was more positive among patients with higher day 0 (median, 5,212 mL [interquartile range, 200-12,284 mL] vs median, 2,020 mL [interquartile range, -2,034 to 7,091 mL]; p < 0.0001) and day 3 soluble suppression of tumorigenicity-2 (median, 7,678 mL [interquartile range, 2,217-14,278 mL] vs median, 1,492 mL [interquartile range, -2,384 to 6,239 mL]; p < 0.0001). Soluble suppression of tumorigenicity-2 showed excellent discriminative ability between the Fluid and Catheter Treatment Trial and heart failure populations (area under receiver-operating characteristic curve = 0.98; p < 0.0001). CONCLUSIONS: Higher soluble suppression of tumorigenicity-2 concentrations are associated with worse outcome in acute respiratory distress syndrome and may have value for discriminating acute respiratory distress syndrome from heart failure.
RCT Entities:
OBJECTIVES: Soluble suppression of tumorigenicity-2 is a biomarker of myocardial strain and inflammation. The characteristics of acute respiratory distress syndrome include inflammation and cardiovascular dysfunction. We sought to determine whether plasma soluble suppression of tumorigenicity-2 concentration is associated with outcome and response to conservative fluid management and whether soluble suppression of tumorigenicity-2 concentration discriminates acute respiratory distress syndrome from decompensated heart failure. DESIGN: A retrospective analysis of the Fluid and Catheter Treatment Trial, a multi-center randomized controlled trial of conservative fluid management in the acute respiratory distress syndrome, as well as of a cohort of patients with decompensated heart failure. SETTING: Twenty acute care hospitals. PATIENTS: Eight hundred twenty-six patients with acute respiratory distress syndrome and 209 patients with acutely decompensated heart failure. MEASUREMENTS AND MAIN RESULTS: Nonsurvivors had higher day 0 (p < 0.0001) and day 3 (p < 0.0001) soluble suppression of tumorigenicity-2 concentrations. After adjustment for severity of illness, higher soluble suppression of tumorigenicity-2 concentration was associated with mortality, with odds ratioadj 1.47 (95% CI, 0.99-2.20; p = 0.06) at day 0, 2.94 (95% CI, 2.00-4.33; p < 0.0001) at day 3, and 3.63 (95% CI, 2.38-5.53; p < 0.0001) if soluble suppression of tumorigenicity-2 increased between days. Cumulative fluid balance was more positive among patients with higher day 0 (median, 5,212 mL [interquartile range, 200-12,284 mL] vs median, 2,020 mL [interquartile range, -2,034 to 7,091 mL]; p < 0.0001) and day 3 soluble suppression of tumorigenicity-2 (median, 7,678 mL [interquartile range, 2,217-14,278 mL] vs median, 1,492 mL [interquartile range, -2,384 to 6,239 mL]; p < 0.0001). Soluble suppression of tumorigenicity-2 showed excellent discriminative ability between the Fluid and Catheter Treatment Trial and heart failure populations (area under receiver-operating characteristic curve = 0.98; p < 0.0001). CONCLUSIONS: Higher soluble suppression of tumorigenicity-2 concentrations are associated with worse outcome in acute respiratory distress syndrome and may have value for discriminating acute respiratory distress syndrome from heart failure.
Authors: A P J Vlaar; W B Honselaar; J M Binnekade; A B Groeneveld; P E Spronk; M J Schultz; N P Juffermans Journal: Acta Anaesthesiol Scand Date: 2009-08-31 Impact factor: 2.105
Authors: Benjamin Dieplinger; James L Januzzi; Martin Steinmair; Christian Gabriel; Werner Poelz; Meinhard Haltmayer; Thomas Mueller Journal: Clin Chim Acta Date: 2009-08-20 Impact factor: 3.786
Authors: Ednan K Bajwa; James L Januzzi; Michelle N Gong; B Taylor Thompson; David C Christiani Journal: Crit Care Med Date: 2008-08 Impact factor: 7.598
Authors: Lorraine B Ware; Tatsuki Koyama; D Dean Billheimer; William Wu; Gordon R Bernard; B Taylor Thompson; Roy G Brower; Theodore J Standiford; Thomas R Martin; Michael A Matthay Journal: Chest Date: 2009-10-26 Impact factor: 9.410
Authors: Carolyn S Calfee; Mark D Eisner; Lorraine B Ware; B Taylor Thompson; Polly E Parsons; Arthur P Wheeler; Anna Korpak; Michael A Matthay Journal: Crit Care Med Date: 2007-10 Impact factor: 7.598
Authors: Marc S Sabatine; David A Morrow; Luke J Higgins; Catherine MacGillivray; Wei Guo; Christophe Bode; Nader Rifai; Christopher P Cannon; Robert E Gerszten; Richard T Lee Journal: Circulation Date: 2008-03-31 Impact factor: 29.690
Authors: Kenjiro Seki; Shoji Sanada; Anastacia Y Kudinova; Matthew L Steinhauser; Vandna Handa; Joseph Gannon; Richard T Lee Journal: Circ Heart Fail Date: 2009-09-22 Impact factor: 8.790
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Daniel Kotok; Libing Yang; John W Evankovich; William Bain; Daniel G Dunlap; Faraaz Shah; Yingze Zhang; Dimitris V Manatakis; Panayiotis V Benos; Ian J Barbash; Sarah F Rapport; Janet S Lee; Alison Morris; Bryan J McVerry; Georgios D Kitsios Journal: J Crit Care Date: 2020-01-13 Impact factor: 3.425
Authors: Georgios D Kitsios; Libing Yang; Dimitris V Manatakis; Mehdi Nouraie; John Evankovich; William Bain; Daniel G Dunlap; Faraaz Shah; Ian J Barbash; Sarah F Rapport; Yingze Zhang; Rebecca S DeSensi; Nathaniel M Weathington; Bill B Chen; Prabir Ray; Rama K Mallampalli; Panayiotis V Benos; Janet S Lee; Alison Morris; Bryan J McVerry Journal: Crit Care Med Date: 2019-12 Impact factor: 7.598
Authors: Matthew W Semler; Annis M Marney; Todd W Rice; Hui Nian; Chang Yu; Arthur P Wheeler; Nancy J Brown Journal: Chest Date: 2016-03-23 Impact factor: 9.410
Authors: Sachiko Seo; Jeffrey Yu; Isaac C Jenkins; Wendy M Leisenring; Terry Steven-Ayers; Jane M Kuypers; Meei-Li Huang; Keith R Jerome; Michael Boeckh; Sophie Paczesny Journal: Biol Blood Marrow Transplant Date: 2017-12-06 Impact factor: 5.742
Authors: Jehan W Alladina; Sean D Levy; Kathryn A Hibbert; James L Januzzi; R Scott Harris; Michael A Matthay; B Taylor Thompson; Ednan K Bajwa Journal: Crit Care Med Date: 2016-09 Impact factor: 7.598
Authors: Jonathan Beaudoin; Jackie Szymonifka; Zachary Lavender; Roderick C Deaño; Qing Zhou; James L Januzzi; Jagmeet P Singh; Quynh A Truong Journal: J Thorac Dis Date: 2019-12 Impact factor: 2.895
Authors: Jehan Alladina; Sean D Levy; Josalyn L Cho; Kelsey L Brait; Sowmya R Rao; Alexander Camacho; Kathryn A Hibbert; R Scott Harris; Benjamin D Medoff; James L Januzzi; B Taylor Thompson; Ednan K Bajwa Journal: Am J Respir Crit Care Med Date: 2021-05-15 Impact factor: 21.405
Authors: Ourania S Kotsiou; Rajesh M Jagirdar; Eleftherios D Papazoglou; Chrissi Hatzoglou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis Journal: Inflammation Date: 2019-12 Impact factor: 4.657